India, Dec. 16 -- Foghorn Therapeutics Inc. (FHTX), Monday said that it decided to discontinue the development of FHD-286 in combination with decitabine to treat patients with acute myeloid leukemia (AML). The company's shares were more than 11 percent down in pre-market trading.
Foghorn said the efficacy data from the Phase 1 study of FHD-286 in combination with decitabine in AML patients did not meet the company's threshold to support continued development by it alone.
Foghorn is evaluating partnerships and Investigator Sponsored Trials to advance FHD-286. The company noted that it will prioritize its proprietary pipeline and Lilly collaboration programs, including the clinical-stage FHD-909.
Foghorn stock had closed at $5.30, down 8.3...